Sarepta Therapeutics, Inc.

AB3A.F·Frankfurt·Healthcare

FollowCompareShare

16.06−0.96 (−5.64%)today

As of Oct 22, 8:05 AM CEST · May be delayed up to 15 min · EUR

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close17.02

Open16.06

Day range—

52-week range12.8221.42

Off day high0.00%

Off 52-week high−25.02%

Volume1.00

Avg. volume (3M)22.00

Market cap1.70B

EPS (TTM)-1.36

Forward P/E-2.80

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)0.38

Shares outstanding105.63M

Short interest—

Earnings dateAug 5, 2026

Analyst target—

Profit margin−6.93%

Against its peers

Compare in full ›

	AB3A.F	DSGN	CAPR	STOK	IONS	TSHA
Market cap	1.70B	655.86M	352.90M	1.70B	7.28B	1.31B
P/E (TTM)	—	—	—	—	—	—
Forward P/E	-2.8	-6.5	-4.2	-7.4	-38.2	-8.7
Price/book	1.2	3.2	1.4	4.7	16.5	3.4
Dividend yield	—	—	—	—	—	—
1-year change	−21.76%	+88.25%	−4.08%	−18.96%	−38.08%	−16.60%
Today	−5.64%	−2.33%	+3.23%	+2.30%	−0.98%	−2.67%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Related companies

Compare ›

Similar businessAlso watched

The businesses closest to AB3A.F's by what they do, from their descriptions, with the same industry weighted in.

Company	Mkt cap	Price	Today
DSGNDesign Therapeutics, Inc.DSGN · Biotechnology	655.86M	10.48	−2.33%
CAPRCapricor Therapeutics, Inc.CAPR · Biotechnology	352.90M	6.07	+3.23%
STOKStoke Therapeutics, Inc.STOK · Biotechnology	1.70B	26.27	+2.30%
IONSIonis Pharmaceuticals, Inc.IONS · Biotechnology	7.28B	43.84	−0.98%
TSHATaysha Gene Therapies, Inc.TSHA · Biotechnology	1.31B	4.0100	−2.67%
RGNXREGENXBIO Inc.RGNX · Biotechnology	475.29M	7.20	+0.42%
NTLAIntellia Therapeutics, Inc.NTLA · Biotechnology	1.57B	11.21	−3.78%
SLDBSolid Biosciences Inc.SLDB · Biotechnology	661.58M	6.17	−3.74%

What visitors to AB3A.F's page also look at.

Company	Mkt cap	Price	Today
J7ZFJazz Pharmaceuticals PLCJ7Z.F	12.23B	188.45	+0.27%
UTHFUNITED THERAPEUTICS CORP.(DEL.RUTH.F	21.30B	496.70	+1.33%
38IFIntellia Therapeutics Inc.38I.F	1.41B	10.08	+0.40%
UP0FUltragenyx Pharmaceutical Inc.RUP0.F	1.38B	13.97	−1.20%
DR6FACADIA PHARMACEUTICALS INC.DR6.F	3.11B	18.06	−0.06%

From the 4Conservative instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All AB3A.F news ›

Defense World·3d agoPositive

Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the…

Markets Daily·4d agoNegative

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Sell-Side Analysts

Posted by Michael Walen on Oct 18th, 2026 Read Our Latest Research Report on Sarepta Therapeutics Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for…

BioSpace·Oct 14

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Details from the SRP-1003 poster presentation: P-066: Preclinical Evaluation of SRP-1003: An αvβ6 Integrin-Targeting siRNA Platform for Targeted Knockdown of DMPK in Myotonic Dystrophy Type 1 (C. Greer, et al.) SRP-1003 also reduced toxic…

The Globe and Mail·Oct 10Negative

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $18.00. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Ultragenyx Pharmaceutical,…

markets.businessinsider.com·Oct 8

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX). In a report released today, Anupam Rama from J.P.…

From articles in the 4Search news index.

In the news

14mentions in 30 days

14with it in the headline

Negativesentiment

Mentioned with

HC Wainwright8Needham & Company Llc7Sarepta Therapeutics Inc.7Amondys6Cartesian Therapeutics6Therapeutics, Inc.6Astrazeneca5JPMorgan Chase & CO5

People in the coverage

Sarepta10Danessa Lincoln9Duchenne9HC Wainwright9Michael Walen9Mitch Edgeman9

Themes

Healthcare9EPS7Srpt7HC Wainwright6Reiterated Rating6Canada4Cartesian Therapeutics4Massachusetts4

Most coverage from

1. themarketsdaily.com4
2. news.alphastreet.com2
3. theglobeandmail.com2
4. biospace.com1
5. businesswire.com1

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.